Efficacy and Safety of HRS9531 Tablet in Obese Subjects

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

166

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Chronic Management of Body Weight

Interventions

DRUG

HRS9531 Tablet

HRS9531 Tablet dose 1

DRUG

HRS9531 Tablet

HRS9531 Tablet dose 2

DRUG

HRS9531 Tablet

HRS9531 Tablet dose 3

DRUG

HRS9531 Tablet placebo

Trial Locations (1)

Nanjing Drum Tower hospital, Nanjing

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06841445 - Efficacy and Safety of HRS9531 Tablet in Obese Subjects | Biotech Hunter | Biotech Hunter